🔥🐔 BizChicken 🐔🔥

Companies Similar to Lyell Immunopharma, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

Engineered T Cell Therapeutics

CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment, particularly targeting hematologic malignancies using innovative immune system integration strategies.

Tags: T cell therapeutics, biotechnology, cancer treatment, hematologic malignancies, immunotherapy

Symbol: CERO

Recent Price: $0.06

Industry: Biotechnology

CEO: Mr. Christopher B. Ehrlich M.B.A.

Sector: Healthcare

Employees: 8

Address: 201 Haskins Way, South San Francisco, CA 94080

Phone: 650-407-2376

Last updated: 2024-12-31

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELI-002

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.

Tags: Biotechnology, Cancer Treatment, Clinical-stage, Immunotherapy, Vaccines

Symbol: ELTX

Recent Price: $5.00

Industry: Biotechnology

CEO: Mr. Robert T. Connelly

Sector: Healthcare

Employees: 32

Address: 451 D Street, Boston, MA 02210

Phone: 857-209-0050

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. logo
Market Cap: Low
Employees: Low

LYL797, LYL845, NY-ESO-1

Lyell Immunopharma, Inc. is a biopharmaceutical company developing T cell therapies focused on treating patients with solid tumors using advanced genetic and epigenetic reprogramming technologies.

Tags: T cell therapy, biotechnology, cancer treatment, epigenetic reprogramming, genetic reprogramming, solid tumors

Symbol: LYEL

Recent Price: $0.62

Industry: Biotechnology

CEO: Dr. Lynn Seely M.D., Ph.D.

Sector: Healthcare

Employees: 224

Address: 201 Haskins Way, South San Francisco, CA 94080

Phone: 650 695 0677

Leadership

  • Lynn Seely, M.D., President & Chief Executive Officer
  • Stephen Hill, Chief Operating Officer
  • Matthew Lang, J.D., Chief Business Officer
  • Gary Lee, Ph.D., Chief Scientific Officer
  • Charles Newton, Chief Financial Officer
  • Ellen Rose, Senior Vice President, Investor Relations and Communications
  • Bryan Selby, Senior Vice President, Clinical Development Operations
  • Ann Tomlin, Senior Vice President, Human Resources
  • Rick Klausner, M.D., Founder & Board Chair
  • Crystal Mackall, M.D., Founder
  • Stan Riddell, M.D., Founder
  • Hans Bishop, Director
  • Otis Brawley, M.D., Director
  • Catherine Friedman, Director
  • Elizabeth Nabel, M.D., Director
  • Robert Nelsen, Director
  • William Rieflin, Director

Last updated: 2024-12-31

Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. logo
Market Cap: Lowest
Employees: Lowest

LP-10, LP-310

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing drugs by reformulating active agents in existing generic drugs for various applications, including LP-10 for radiation-induced hemorrhagic cystitis and LP-310 for oral lichen planus.

Tags: biotechnology, clinical-stage, drug development, hemorrhagic cystitis, oral lichen planus, pharmaceuticals, reformulation

Symbol: LIPO

Recent Price: $3.12

Industry: Biotechnology

CEO: Dr. Jonathan Kaufman M.B.A., Ph.D.

Sector: Healthcare

Employees: 5

Address: 7800 Susquehanna St., Pittsburgh, PA 15208

Phone: 412-894-1853

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. logo
Market Cap: Lowest
Employees: Not Available

EB103, EB104

Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company that develops T-cell therapies for blood cancers and solid tumors, with product candidates such as EB103 and EB104. It collaborates with Imugene Limited to develop solid tumor treatments.

Tags: EB103, EB104, Imugene Limited, T-cell therapies, biopharmaceutical, blood cancer, clinical trial, collaboration, solid tumors

Symbol: ESLA

Recent Price: $1.24

Industry: Biotechnology

CEO: Dr. Cheng Liu Ph.D.

Sector: Healthcare

Employees: N/A

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 318 9098

Last updated: 2024-12-31

HilleVax, Inc.

HilleVax, Inc. logo
Market Cap: Low
Employees: Low

HIL-214

Hille Vax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines, including HIL-214, for the prevention of norovirus infection.

Tags: biopharmaceutical, clinical-stage, norovirus, vaccines

Symbol: HLVX

Recent Price: $1.98

Industry: Biotechnology

CEO: Dr. Robert M. Hershberg M.D., Ph.D.

Sector: Healthcare

Employees: 90

Address: 75 State Street, Boston, MA 02109

Phone: 617 213 5054

Last updated: 2024-12-31

Immuneering Corporation

Immuneering Corporation logo
Market Cap: Lowest
Employees: Low

IMM-1-104 and IMM-6-415

Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates, with key products like IMM-1-104 for cancer treatment and IMM-6-415 for solid tumors.

Tags: biopharmaceutical, cancer treatment, drug development, neuroscience, oncology

Symbol: IMRX

Recent Price: $2.25

Industry: Biotechnology

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

Sector: Healthcare

Employees: 66

Address: 245 Main Street, Cambridge, MA 02142

Phone: 617 500 8080

Last updated: 2024-12-31

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. logo
Market Cap: High
Employees: Medium

lifileucel

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing cancer immunotherapy products to utilize the immune system in eradicating cancer cells, with several ongoing phase 2 clinical studies.

Tags: biotechnology, cancer immunotherapy, cancer treatment, clinical-stage, lifileucel

Symbol: IOVA

Recent Price: $7.17

Industry: Biotechnology

CEO: Dr. Frederick G. Vogt Esq., J.D., Ph.D.

Sector: Healthcare

Employees: 557

Address: 825 Industrial Road, San Carlos, CA 94070

Phone: 650 260 7120

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Relay Therapeutics, Inc.

Relay Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

RLY-4008, RLY-2608, RLY-1971

Relay Therapeutics, Inc. is a clinical-stage company that focuses on precision medicine in oncology and genetic diseases by transforming the drug discovery process. Their leading products include small molecule inhibitors for advanced cancer treatment.

Tags: FGFR2, PI3Ka, Src homology, clinical-stage, drug discovery, genetic diseases, oncology, precision medicines, small molecule inhibitors

Symbol: RLAY

Recent Price: $4.18

Industry: Biotechnology

CEO: Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

Sector: Healthcare

Employees: 323

Address: 399 Binney Street, Cambridge, MA 02139

Phone: 617 370 8837

Last updated: 2024-12-31

Rallybio Corporation

Rallybio Corporation logo
Market Cap: Lowest
Employees: Lowest

RLYB212

Rallybio Corporation is a clinical-stage biotechnology company focused on discovering, developing, manufacturing, and delivering therapies for severe and rare diseases, with a lead product candidate RLYB212 in clinical trials.

Tags: biotechnology, clinical trials, monoclonal antibodies, rare diseases, therapeutics

Symbol: RLYB

Recent Price: $0.93

Industry: Biotechnology

CEO: Dr. Stephen Uden M.B, M.D.

Sector: Healthcare

Employees: 25

Address: 234 Church Street, New Haven, CT 06510

Phone: 203 859 3820

Last updated: 2024-12-31

Instil Bio, Inc.

Instil Bio, Inc. logo
Market Cap: Low
Employees: Lowest

ITIL-168, ITIL-306

Instil Bio, Inc. is a clinical-stage biopharmaceutical company that develops cell therapies for treating cancer patients, focusing on autologous tumor infiltrating lymphocyte (TIL) treatments.

Tags: TIL, biopharmaceutical, cancer therapy, cell therapy, clinical-stage

Symbol: TIL

Recent Price: $18.99

Industry: Biotechnology

CEO: Mr. Bronson Crouch

Sector: Healthcare

Employees: 49

Address: 3963 Maple Avenue, Dallas, TX 75219

Phone: 972 499 3350

Last updated: 2024-12-31

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTX101

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.

Tags: biotechnology, cancer treatment, checkpoint inhibitors, clinical-stage, immunotherapies

Symbol: XLO

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Rene Russo BCPS, Pharm.D.

Sector: Healthcare

Employees: 73

Address: 828 Winter Street, Waltham, MA 02451

Phone: 617 430 4680

Last updated: 2024-12-31

Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

DANYELZA

Y-m Abs Therapeutics, Inc., is a commercial-stage biopharmaceutical company focused on developing and commercializing novel antibody-based therapeutic products for cancer treatment in the United States.

Tags: DANYELZA, antibody, biopharmaceutical, cancer treatment, clinical trials

Symbol: YMAB

Recent Price: $7.76

Industry: Biotechnology

CEO: Mr. Michael Rossi

Sector: Healthcare

Employees: 100

Address: 230 Park Avenue, New York, NY 10169

Phone: 646 885 8505

Leadership

  • Michael Rossi, President and Chief Executive Officer
  • Thomas Gad, Founder, Vice Chairman of the Board of Directors, Chief Business Officer
  • Torben Lund-Hansen, SVP, Chief Technical Officer
  • Peter Pfreundschuh, Chief Financial Officer
  • Vignesh Rajah, SVP, Chief Medical Officer
  • Joris Wilms, SVP, Chief Operating Officer
  • Sue Smith, SVP, Chief Commercial Officer
  • Norman LaFrance, Chief Development Officer
  • Johan Wedell-Wedellsborg, Chairman
  • Ashutosh Tyagi, M.D.,
  • James I. Healy, Chairman
  • David N. Gill,
  • Laura J. Hamill,
  • Mary Tagliaferri, M.D.,

Last updated: 2024-12-31

Immix Biopharma, Inc.

Immix Biopharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

IMX-110, IMX-111, IMX-120

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.

Tags: Biopharmaceuticals, Clinical Trials, Inflammation, Oncology, Tissue-Specific Therapeutics

Symbol: IMMX

Recent Price: $2.36

Industry: Biotechnology

CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.

Sector: Healthcare

Employees: 14

Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064

Phone: 310 651 8041

Last updated: 2024-12-31

Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010

Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.

Tags: ALS, Parkinson's disease, Sanfilippo syndrome, biopharmaceutical, central nervous system, major depressive disorder, respiratory disorders, therapeutics

Symbol: SEEL

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Raj Mehra J.D., Ph.D.

Sector: Healthcare

Employees: 8

Address: 300 Park Avenue, New York, NY 10022

Phone: 646 293 2100

Last updated: 2024-12-31